Table 4.

Pooled AIR and cumulative amount of FVIII in PwHAs without FVIII inhibitors across 24-week treatment intervals in the HAVEN 3 and 4 studies

Treatment for bleed	Weeks 1-24	Weeks 25-48	Weeks 49-72	Weeks 73-96	Weeks 97-120	Weeks 121-144
Evaluable participants, n	186	182	175	154	127	112
FVIII AIR	3.3 (0.8-9.2)	3.7 (0.9-9.8)	3.4 (0.8-9.4)	2.1 (0.3-7.4)	2.0 (0.2-7.2)	2.5 (0.4-8.0)
FVIII, U/kg	101.6 (82.8-123.4)	107.6 (88.3-130.0)	100.4 (81.7-122.1)	62.9 (48.3-80.5)	56.7 (42.9-73.5)	71.5 (55.9-90.2)

Unless otherwise noted, data are mean (95% CI).

A total of 191 PwHAs without FVIII inhibitors were included in the efficacy analysis, because 1 participant in HAVEN 3 assigned to no prophylaxis was lost to follow-up and not treated. This patient was excluded from the efficacy analysis.